BCM
XENE icon

Boone Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Boone Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-250,460
Closed -$9.77M – 21
2024
Q2 		$9.77M Sell
250,460
-40,943
-14% -$1.64M 2.55% 16
2024
Q1 		$12.5M Buy
291,403
+35,971
+14% +$1.65M 2.54% 17
2023
Q4 		$11.8M Buy
+255,432
New +$9.02M 2.75% 17

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Boone Capital Management's XENE Position: Q3 2024 in Review

Boone Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2024, closing a stake of 250,460 shares — an estimated $9.77M sold.

Boone Capital Management first reported a position in XENE in Q4 2023 and held it in 3 quarters. The position peaked at $12.5M in Q1 2024. 203 funds tracked by Wall St. Rank hold XENE as of Q3 2024.

  • Boone Capital Management reported no remaining Xenon Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Boone Capital Management sold 250,460 Xenon Pharmaceuticals shares in Q3 2024, an estimated $9.77M.
  • Boone Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Boone Capital Management's Xenon Pharmaceuticals position peaked at $12.5M in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2024.

Based on Boone Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.